뉴스벤징가
Small Biotech Context Therapeutics Reports 29% Response Rate In Ovarian Cancer Study
· 발표
기사 요약
Context Therapeutics reports 29% ORR in evaluable ovarian cancer patients treated with CTIM-76, with favorable safety data.
기사 원문에서 발췌했어요.Context Therapeutics reports 29% ORR in evaluable ovarian cancer patients treated with CTIM-76, with favorable safety data.
기사 원문에서 발췌했어요.
댓글 —
댓글을 불러오고 있어요…